NLRP3 oligonucleotide for use in preventing and/or treating an inflammatory disease
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Feb 20, 2025
app pub date -
Dec 23, 2022
filing date -
Dec 23, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention refers to oligonucleotide consisting of 12 to 20 nucleotides comprising at least one modified nucleotide hybridizing with a nucleic acid sequence of NLR family pyrin domain containing 3 (NLRP3) and a pharmaceutical composition 5 comprising such oligonucleotide together with a pharmaceutically acceptable carrier, excipient and/or dilutant to inhibit the expression of NLRP3 for example for preventing and/or treating an inflammatory disease.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully